References
Bone RC. Gram-negative sepsis. Background, clinical features and intervention. Chest 1991; 100: 802–8
Babineau TJ, Marcello P, Swails W, et al. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994; 220(5): 601–9
Williams DL, Mueller A, Browder W. Glucan-based macrophage stimulators. Clin Immunother 1996; 5(5): 392–9
Williams DL, McNamee RB, Jones EL, et al. A method for the solubilization of a (l-3)-β-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr Res 1991; 219: 203–13
Jamas S, Chen Y-CJ, von der Osten CH, et al. Spectral analysis of glucan produced by wild-type and mutant Saccharomyces cerevesiae. Carbohydr Polym 1990; 13: 207–19
Babineau TJ, Hackford A, Kenler A, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129: 1204–10
Browder W, Williams D, Pretus H, et al. Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg 1990; 211: 605–13
Felippe J, Silva M, Maciel FM, et al. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynecol Obstet 1993; 177: 383–8
Rights and permissions
About this article
Cite this article
Glucan-based macrophage stimulators may prevent infections in trauma and surgical patients. Drugs Ther. Perspect 8, 6–7 (1996). https://doi.org/10.2165/00042310-199608040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199608040-00002